BioSpace - Print News Article

Resverlogix Corporation (RVX.TO) Announces New Data on Autoimmune Program Featured at World Congress of Inflammation 6/28/2011 6:06:05 AM TSX Exchange Symbol: RVX CALGARY, June 27, 2011 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that key scientific data has been presented in a poster presentation highlighting the novel features of RVX-297, at the 10th World Congress on Inflammation, in Paris, France (poster number P-296, June 27 at 1 pm). The presentation is entitled "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases Clinical Signs In A Mouse Model Of Multiple Sclerosis." "RVX-297 is a representative molecule from our autoimmune program, which was established to expand upon important discoveries made during our investigative research on pharmacological approaches for controlling the inflammatory components of atherosclerosis," stated Don McCaffrey, President & CEO of Resverlogix. Mr. McCaffrey continued, "Autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis and Crohn's disease currently represent a significant unmet medical need globally. The novel, orally bioavailable small molecule drugs under development by Resverlogix possess unique immunopharmacological properties and have the potential to compete effectively against expensive protein-based therapeutics which currently dominate the autoimmune market." The poster presentation includes data demonstrating that RVX-297 both prevents onset of and treats established disease in murine experimental autoimmune encephalomyelitis (EAE), a well-accepted animal model of multiple sclerosis (MS). The effects in the treatment model included a dramatic reduction in clinical signs, histopathological evidence of disease, and expression of inflammatory biomarkers of disease. Dr. Gregory. S. Wagner, Sr. Vice President of R&D, further stated "RVX-297 also blocked the production of the cytokines IL-6 and IL-17, which are believed to be critical mediators in development of the autoimmune response in this model. Resverlogix is very excited about these results with RVX-297 because blocking IL-6 or IL-17 has shown evidence of clinical benefit in a number of autoimmune indications, suggesting that this new class of molecules, which combine the two activities in an oral formulation, may be effective in a range of autoimmune diseases." About Resverlogix Corp. Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's research in autoimmune disorders represents a second important therapeutic research area of high unmet medical need. These therapies are targeted to address the increasing incidence of autoimmune disorders such as multiple sclerosis (MS) and other inflammatory disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com. This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases, multiple sclerosis, rheumatoid arthritis, Crohn's and other autoimmune disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release. SOURCE Resverlogix Corp.

Resverlogix Corporation (RVX.TO) Announces New Data on Autoimmune Program Featured at World Congress of Inflammation
6/28/2011 6:06:05 AM

TSX Exchange Symbol: RVX

CALGARY, June 27, 2011 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today that key scientific data has been presented in a poster presentation highlighting the novel features of RVX-297, at the 10th World Congress on Inflammation, in Paris, France (poster number P-296, June 27 at 1 pm). The presentation is entitled "An Orally Bioavailable Small Molecule RVX-297 Significantly Decreases Clinical Signs In A Mouse Model Of Multiple Sclerosis."

"RVX-297 is a representative molecule from our autoimmune program, which was established to expand upon important discoveries made during our investigative research on pharmacological approaches for controlling the inflammatory components of atherosclerosis," stated Don McCaffrey, President & CEO of Resverlogix.

Mr. McCaffrey continued, "Autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, psoriasis and Crohn's disease currently represent a significant unmet medical need globally. The novel, orally bioavailable small molecule drugs under development by Resverlogix possess unique immunopharmacological properties and have the potential to compete effectively against expensive protein-based therapeutics which currently dominate the autoimmune market."

The poster presentation includes data demonstrating that RVX-297 both prevents onset of and treats established disease in murine experimental autoimmune encephalomyelitis (EAE), a well-accepted animal model of multiple sclerosis (MS). The effects in the treatment model included a dramatic reduction in clinical signs, histopathological evidence of disease, and expression of inflammatory biomarkers of disease. Dr. Gregory. S. Wagner, Sr. Vice President of R&D, further stated "RVX-297 also blocked the production of the cytokines IL-6 and IL-17, which are believed to be critical mediators in development of the autoimmune response in this model. Resverlogix is very excited about these results with RVX-297 because blocking IL-6 or IL-17 has shown evidence of clinical benefit in a number of autoimmune indications, suggesting that this new class of molecules, which combine the two activities in an oral formulation, may be effective in a range of autoimmune diseases."

About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas PR program is the Company's primary focus which is to develop novel small molecules that enhance ApoA-1 production. These vital therapies are focused to address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders. The Company's research in autoimmune disorders represents a second important therapeutic research area of high unmet medical need. These therapies are targeted to address the increasing incidence of autoimmune disorders such as multiple sclerosis (MS) and other inflammatory disorders. Resverlogix Corp.'s common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information please visit www.resverlogix.com.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, including our statements with respect to research, development and commercialization of novel therapeutics that reduce the risk of cardiovascular and autoimmune diseases including atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular diseases, multiple sclerosis, rheumatoid arthritis, Crohn's and other autoimmune disorders that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous known and unknown risks and uncertainties including but not limited to those risk factors discussed in the Company's Annual Information Form and January 31, 2011 MD&A which are incorporated herein by reference and other documents we file from time to time with securities authorities, which are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The TSX Exchange does not accept responsibility for the adequacy or accuracy of this news release.

SOURCE Resverlogix Corp.